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Summary Expression of the MRP gene has been demonstrated in vitro to be a causal factor in non-P-
glycoprotein-mediated multidrug resistance, and is implicated in resistance to a number of the
chemotherapeutic agents currently used in the treatment of high-grade transitional cell carcinoma (TCC) of
the bladder (doxorubicin, epirubicin and vinblastine). Using a sensitive RT-PCR-based technique, we have
quantified MRP mRNA levels in a series of untreated TCC (n =24), normal bladder (n =5) and control tissue
and cell line samples. MRP mRNA was widely expressed and detectable in all samples analysed, with
considerable (up to 190-fold) variation observed between individual tumour samples. MRP mRNA levels found
in TCC samples were lower than those determined for normal peripheral mononucleocyte (2.3-fold) and testis
(4.1-fold) samples, previously reported to be high-expressing tissues, and varied over a similar range to that
observed in normal bladder samples. Results indicate that MRP mRNA levels in a greater proportion ofhigh-
grade (G3) bladder tumours (55%, 6/11) are significantly reduced (P=0.018) compared with low- and
moderate-grade (G1/2) bladder tumours (8%, 1/13), and suggest that MRP mRNA levels frequently become
reduced as a consequence of tumour progression to advanced, poorly differentiated disease. No correlation was
apparent between MRP and MDRJ mRNA levels, thus providing no evidence to suggest common regulation
of the two genes. In a limited number of patients, no evidence was found to support a role for MRP mRNA
levels as a determinant of response to chemotherapy in patients being uniformly treated with either cisplatin-
methotrexate-vinblastine (n=6) or epirubicin-cisplatin -methotrexate (n=4) regimens. Similarly, no overall
pattern of altered MRP mRNA expression was observed following chemotherapy in four patients from whom
post chemotherapy biopsies were taken. This study provides a useful pilot investigation regarding the level,
variation and pattern of MRP mRNA expression in TCC of the bladder, and suggests that further studies to
establish the clinical significance of these variations are required.
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Transitional cell carcinoma (TCC) of the bladder represents
the fifth most prevalent malignancy in Western populations,
with peak incidence found in males of the 60- to 70-year-old
age group (Davies, 1982). TCCs arise from the specialised
urinary epithelium (urothelium) and comprise >90% of all
bladder tumours. TCCs are clinically classified by their degree
of bladder wall invasion (Stage; Ta to T4; UICC, 1978) and
their degree ofde-differentiation (Grade; GI to G3) (reviewed
by Mostofi et al., 1988). Muscle-invasive tumours (T2, T3
and T4) are routinely treated using chemotherapy regimens
based on the cytotoxic agents cisplatin, methotrexate,
vinblastine and doxorubicin, with total response rates of
60% (30% complete) commonly observed in previously
untreated patients (Harker et al., 1985; Sternberg et al.,
1988). However, a large proportion (approximately 40%) of
bladder tumours do not respond to chemotherapy, and the
reasons underlying this treatment failure remain to be
elucidated. Molecular mechanisms that mediate cellular drug
resistance may play a role in the differential responsiveness of
individual bladder tumours to chemotherapy.
The multidrug resistance-associated protein (MRP) is a
190 kDa membrane phosphoglycoprotein belonging to the
ATP-binding cassette family of transporter proteins, to which
the transmembrane drug efflux pump, P-glycoprotein
(encoded by the MDRJ gene), also belongs (Cole et al.,
1992; Endicott and Ling, 1989). However, while MRP shares
many of the structural and functional features of P-
glycoprotein, the two proteins share only 15% amino acid
identity (Cole et al., 1994; Almquist et al., 1995). Since its
cloning and identification from the doxorubicin-selected
small-cell lung cancer (SCLC) cell line, H69/AR (Cole et
al., 1992), the degree of overexpression of the 6.5 kb MRP
mRNA has been shown to correlate well with the multidrug
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resistance (MDR) phenotype of a number of doxorubicin-
selected cell lines of different origin that do not overexpress
P-glycoprotein (P-gp), including H69/AR, GLC4/ADR
(SCLC; Zaman et al., 1993), HL60/ADR (acute myeloid
leukaemia; Marsh et al., 1986), HT1080/DR4 (fibrosarcoma;
Slovak et al., 1993), COR-L23/R (large-cell lung carcinoma;
Barrand et al., 1994) and T24/ADM-2 (TCC of the bladder,
Hasegawa et al., 1995), with MRP overexpression widely
associated with reduced intracellular drug accumulation.
Gene transfection studies (Grant et al., 1994; Cole et al.,
1994) have demonstrated that introduction of the full-length
MRP cDNA into HeLa cells confers a typical MDR
phenotype, displaying cross-resistance to the anthracyclines
(doxorubicin, daunorubicin, epirubicin), vinca alkaloids
(vincristine, vinblastine), VP16 and taxol, but not mitoxan-
trone, 9-alkyl anthracyclines or cisplatin. ATP-dependent
reduced drug accumulation was also observed in these
transfectants which, coupled with recent monoclonal anti-
bodies studies demonstrating localisation of the MRP protein
to the plasma membrane in MRP transfectants and over-
expressing cells by Flens et al. (1994), Hipfner et al. (1994)
and Almquist et al. (1995), is highly suggestive of a role for
MRP as an energy-dependent transmembrane drug efflux
pump. Recent studies have suggested that in some cells, MRP
may alternatively or in addition be involved in the
intracellular sequestration and redistribution of drugs away
from their site of action (Cole et al., 1992; Almquist et al.,
1995), and in the ATP-dependent transport of glutathione S-
conjugates across the cell membrane, thus providing a
potential role for MRP in the removal of glutathione-
conjugated xenobiotics from the cell (Muller et al., 1994).
Expression of the MRP gene is implicated in tumour cell
resistance to many of the drugs currently used in the
chemotherapy of bladder cancer (epirubicin, doxorubicin
and vinblastine). However, the clinical relevance of MRP
gene expression in human tumours remains unclear, with few
studies having investigated the variation and pattern of MRPMRP gene expression in human bladder cancer
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expression within a specific tumour type, or related this to the
subsequent response to chemotherapy. This study reports the
determination of MRP gene transcript levels in a series of
previously untreated bladder TCC, and relates these levels to
clinical and histopathological features including tumour
stage, grade, progression and recurrence, as well as
expression levels in the normal, non-neoplastic bladder. In
addition, the relationship between inter-tumour variation in
pretreatment tumour MRP mRNA levels and the response to
chemotherapy is examined, and MRP mRNA levels are
evaluated in bladder tumour biopsies taken following
treatment by chemotherapy. Associations between the
relative transcript levels of the MDRI and MRP genes in a
cohort of untreated bladder tumours are also investigated.
Materials and methods
Tumours, tissues and cell lines
TCC tumour samples were obtained at presentation by local
resection or cystectomy from the primary tumour site. The
mean tumour sample mass was 1.35 (± 0.21 s.e.) g with a
minimum value of 0.18 g and a maximum of 5.46 g. A
portion of the sample was sent for histological evaluation of
tumour differentiation, and the extent of tumour invasion
was assessed according to UICC (1978) criteria by
histopathological examination, computerised tomography
(CT) scan and bimanual palpation. Patient metastases were
assessed by chest radiograph and CT scan of the regional
lymph nodes. Care was taken to limit the proportion of
tumour sample contaminated by normal tissue. The
papillary growth pattern of superficial tumours allowed
their routine resection without contamination by underlying
normal tissue. Despite their involvement with the underlying
lamina propria and muscle, contamination of muscle-
invasive tumours with normal tissue was minimised by
only selecting material from the protruding tumour mass.
Although it was more difficult to ensure complete
elimination of normal tissue from these samples, histologi-
cal examination indicated an upper limit of 10-15%
contamination by normal tissue. None of the patients
described had received prior treatment by chemotherapy.
Normal bladder samples from patients undergoing radical
cystectomy for non-neoplastic conditions were obtained as
either whole bladder wall or as pure urothelium, which was
carefully stripped away from its underlying tissue. Testicular
tissue from a patient undergoing orchidectomy and periph-
eral mononucleocytes were used as positive controls during
the validation of the MRP transcript assay, since they had
been described in the literature as tissues showing high MRP
expression. All tumour and tissue samples were immediately
snap frozen in liquid nitrogen and transferred to a -70°C
freezer for storage. Peripheral mononuclear cells were
separated from whole blood taken from normal healthy
individuals by centrifugation (1100 g, 15 min) over a sodium
metrizoate/Ficoll solution (Lymphoprep; Nycomed UK),
followed by washing in phosphate-buffered saline (PBS) and
pelleting by centrifugation (550 g, 5 min), before storage at
-70°C. All precedures were performed at 4°C.
GLC4 SCLC cells and theirdoxorubicin-selected multidrug-
resistant variant, GLC4/ADR (Zijlstra et al., 1987), which
overexpresses MRP mRNA in the absence of P-glycoprotein
overexpression (Zaman et al., 1993), were used as additional
validation controls. Both lines tested mycoplasma-negative,
and were routinely grown as adherent cells in RPMI-1640
medium (Gibco) supplemented (final concentrations) with 10%
fetal calf serum, L-glutamine (2 mM), sodium bicarbonate
(0.2%) (all Gibco) and sodium hydroxide (120 mM). Doxor-
ubicin was added to the media at a final concentration of
0.64 Mug ml-'(GLC4/ADR cells only). Both lines were grown
at 37°C in a humidified incubator at a 5% carbon dioxide
concentration, and subcultured twice weekly. Cells were
harvested at 70% confluence by scraping in PBS at 4°C, and
pelleted by low-speed centrifugation (550 g, 5 min) before
freezing at -70°C.
Chemotherapy protocols and post chemotherapy tumour
samples
Patients with muscle invasive bladder tumours received first-
line chemotherapy using either the CMV (3 consecutive 21
day cycles comprising: 100 mg m-2 cisplatin (day 1),
30 mg m-2 methotrexate (days 1 and 8), 4 mg m-2 vinblas-
tine (days 1 and 8)) or EPICM (2 consecutive 21 day cycles
comprising: 50 mg m-2 epirubicin (day 1), 70mg m-2
cisplatin (day 1), 40 mg m-2 methotrexate (days 8 and 15))
regimens. Tumour response was assessed 1 -3 weeks
following the end of the final treatment cycle by
histopathological examination, CT scan and bimanual
palpation, at which time post chemotherapy tumour biopsies
were obtained from partially responding patients. Tumour
response was categorised as complete response (CR; complete
disappearance of all clinical evidence of tumour), partial
response (PR; >50% reduction in the tumour mass, with no
simultaneous increase in size of any lesion), no change (NC;
<50% reduction or <25% increase in tumour mass) or
progressive disease (PD; >25% increase in tumour mass or
development of metastic disease). All assessments were based
on the product of the two largest diameters of the bladder
tumour mass.
Determination of mRNA levels by quantitative PCR-based
gene transcript assay
MRP and MDR] mRNA levels were determined in all
samples relative to those of 18SrRNA as an internal reference
standard, using a previously described sensitive gene
transcript assay based on reverse transcription and the
polymerase chain reaction (RT-PCR) (Clifford et al., 1994).
Optimisation ofthepolymerase chain reaction Oligonucleotide
primers that recognise the MRP and 18SrRNA cDNA
sequences were selected using the computer program
designed by Lowe et al. (1990). These were (in 5' to 3'
orientation); MRP, sense strand ACTCCAACGCTGACAT-
TTACC and antisense strand AAGTAGCTCATGCTG-
TGCG (residues 2545-2565 and 2674-2692 respectively;
Cole et al., 1992), and 18SrRNA, sense strand ATGCTCT-
TAGCTGAGTGTCC and antisense strand AACTACGAC-
GGTATCTGATC (residues 864-883 and 1154-1175
respectively; Gonzalez and Schmikel, 1986). The MDR]
primer sequences used were those previously described by
Noonan et al. (1990). The primers yielded PCR products of
148 bp (MRP), 167 bp (MDRJ) and 311 bp (18SrRNA), and
optimal magnesium chloride concentrations of 1 mM, 2.5 mM
and 1 mm were determined for each of the primer pairs
respectively. MRP and MDR] primers were each shown to
produce differentially sized PCR products when cDNA and
genomic DNA were used as reaction templates, and thus
distinguish and discriminate any contaminating genomic
DNA present in cDNA stocks by virtue of their spanning
an intronic region.
Determination of gene transcript levels Serial cDNA dilu-
tions for each species of interest were simultaneously and
independently amplified over 25 PCR cycles (94°C for 1 min,
56°C for 1 min, 72°C for 1 min) using otherwise fixed
reaction conditions, followed by electrophoretic separation
and quantitative analysis of the radiolabelled PCR products
using a Phosphorimager (Molecular Dynamics), as previously
described (Clifford et al., 1994). A typical Phosphorimager
image of the separated products is shown in Figure la. For
each species, the amount of PCR product (incorporated
radioactivity) was plotted against input cDNA dilution
(Figure Ib). Regression analysis was performed on the
points falling on the linear range of amplification for each
species. The gene transcript level relative to that of a
reference gene is essentially measured as the ratio of cDNA
dilutions required to yield a given amount of PCR product
on the linear portion of the product vs input cDNA curve
(see Clifford et al., 1994). MRP and MDRI mRNA levelsmeasured relative to 18SrRNA were thus expressed as MRP/
18SrRNA and MDRJ/18SrRNA ratios respectively. For each
cDNA sample, at least three replicates of the assay were
performed, and the results analysed to give a mean (± s.e.)
ratio, which represents the relative mRNA levels of the target
and reference genes for the RNA sample. Extensive
validations of this technique with respect to sensitivity,
reproducibility and PCR amplification efficiency have
previously been reported (Clifford et al., 1994).
Results
MRP gene transcript levels in normal and TCC bladder
samples
MRP mRNA levels were determined in 24 previously
untreated TCC (by stage; Ta, n=8; T1, n= 5; T2, n= 1, T3,
n=9; T4, n= 1; and by grade; GI, n=4; G2, n=9; G3,
n= 11) and 5 normal bladder samples. In addition, one testis
sample and two white blood cell samples (tissues previously
reported to express high levels of MRP mRNA (Cole et al.,
1992)) and cell lines with differential MRP mRNA levels
(GLC4 and GLC4/ADR; Zaman et al., 1993) were also
assayed as positive controls. Results are shown in Figure 2.
The mean standard error for repeat determinations (n>3) on
any given sample was 27%, based on all samples analysed
(n =40).
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Quantifiable levels of MRP mRNA were detected in all
samples analysed. The pooled mean MRP mRNA level
(MRP/18SrRNA ratio) for all untreated bladder tumour
samples was 2.0 (±2.2) x IO-i (mean + s.d., n=24), with
considerable variation observed between individual tumours
(over a 189-fold range; highest, 1.1 x 10-4; lowest, 5.9 x 10-7;
coefficient of variation, 111%). The pooled mean MRP
mRNA level determined for normal bladder samples was 2.97
(±2.06) x 10- (mean + s.d.), with the levels observed in
individual samples varying over a comparable range (31-fold;
high, 4.9 x 10-5; low, 1.6 x 10-6; coefficient of variation,
70%) to that observed for bladder tumours. Based on the
limited numbers of normal bladder samples analysed, no
differences were apparent between the MRP mRNA levels
observed in groups of whole bladder wall and stripped
urothelium normal bladder samples. This was reflected by no
significant difference (t-test, P=0.64) being observed between
paired urothelium and bladder wall samples taken from a
single individual patient [4.94 (+ 1.23) x 10- vs 4.28 (+
0.39)x 10-5; mean + s.e., nk3]. MRP mRNA levels in
tissues previously reported to show high levels of expression
were higher than the mean level of expression found in
bladder tumours (white blood cells, approximately 2.3-fold
higher; testis, approximately 4.1-fold higher). MRP mRNA
levels in drug-resistant MRP-overexpressing GLC4/ADR
cells were 24-fold higher than those detected in their drug-
sensitive parental GLC4 cells. This result is in close
agreement with the 25-fold overexpression of MRP mRNA
previously reported in these cells (by RNAase protection
assay; Zaman et al., 1993), and the 20-fold overexpression
that we have independently detected by Northern blot
analysis (SC Clifford, 1994).
Relationships to tumour stage and grade
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Figure 1 (a) Example of products produced from simultaneous
independent amplification over 25 PCR cycles of serial cDNA
dilutions derived from a peripheral mononucleocyte sample for
MRP and 18SrRNA, following separation by polyacrylamide gel
electrophoresis and visualisation by Phosphorimaging. (b) A log-
log plot ofproduct produced vs the initial amount ofinput cDNA
for the two series of points shown in (a). A, MRP; 0, 18S
rRNA. The linear ranges of amplification are highlighted for each
species by black arrows, and characteristic flanking regions of
reaction threshold and plateau are indicated.
Figure 3a shows MRP mRNA levels determined for all TCC
and normal bladder samples analysed, displayed with respect
to histological grade and degree of invasiveness. With the
exception of two tumours which presented as T3 G2 and TI
G3, all invasive (T2/3/4) tumours also presented as high
grade (G3). These results suggest a cluster of tumours with
low-MRP mRNA levels (MRP/18S ratio <1 x 10-5) in the
high-grade and invasive groups of tumours, and demonstrate
that low-MRP mRNA levels (MRP/18S ratio <1 x 10-5)
were found in 55% (6/11) of G3 tumours, compared with
only 8% (1/13) of G1/2 tumours (P=0.018, Fisher's exact
test). By pooled mean analysis, similar MRP mRNA levels
were found in groups of high-grade (G3, n= 13) and low-
grade (G1/2, n= 11) tumours (t-test, P=0.807), and in groups
of superficial (Ta/1, n= 13) and invasive (T2/3/4, n= I1)
tumours (t-test, P=0.996). However, these results are biased
by the inclusion in the analysis of an individual high-grade/
invasive tumour with very high MRP mRNA levels (4-fold
higher than any other high-grade/invasive tumour). The high
MRP mRNA levels observed in the outlying sample were
confirmed upon repeat investigation (data not shown), and
removal ofthis single point from the stage and grade analyses
revealed that both pooled mean and median MRP mRNA
levels are significantly lower in high-grade tumours than low-
and moderate-grade tumours (t-test, P=0.014; Mann-
Whitney test, P=0.014). Similar results are obtained in
comparisons of superficial and invasive groups of tumours,
although an equivalent level of significance is not reached (t-
test, P=0.062; Mann-Whitney test, P=0.058). Thus, these
results indicate a trend towards lower MRP mRNA
expression in a subset of high-grade bladder tumours.
Relationships to tumour recurrence andprogression
The potential usefulness of MRP mRNA levels as a marker
of superficial tumour behaviour and prognosis was investi-
gated. No evidence was found to suggest a relationship
between MRP mRNA levels and the rate of tumour
recurrence (linear regression analysis, r2=0.007, n= 12) in
the group of superficial bladder tumours analysed. Similarly,
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no significant differences (t-test, P =0.38) were found between
pooled mean MRP mRNA levels in groups of progressing
[1.5 (± 0.9) X 10-5, n=4] and non-progressing [2.1 (+
1.3) x 10-5, n=9] superficial bladder tumours (both mean
± s.e.).
MRP mRNA levels and the response to chemotherapy
MRP mRNA levels varied over a 45-fold range (5.9 + 10-7
to 2.69 x 10-5) in patients proceeding to receive the CMV
chemotherapy regimen (n=6), and a 56-fold range
(1.95 x lo-6 to 1.10 x 10-s) in patients receiving EPICM
therapy (n=4). Figure 4a demonstrates that in the limited
number of patients investigated to date, no evidence was
found to suggest an association between high pretreatment
MRP mRNA levels and resistance to either chemotherapy
regimen. Furthermore, it is notable that the patient with the
highest tumour MRP mRNA levels had a partial response to
the CMV regimen.
MRP mRNA levelsfollowing treatment by chemotherapy
In four cases, MRP mRNA levels were determined in paired
post chemotherapy samples taken 2-3 weeks following the
end of chemotherapy from partially responding patients.
Results are summarised in Figure 4b. Three patients had
marginally increased MRP mRNA levels following treatment
(patient 1, 2.4-fold; patient 2, 1.6-fold; patient 4, 1.7-fold),
however for only one of these (patient 1) was the difference
of borderline significance (P=0.075). None of the elevated
post treatment levels observed exceeded the mean MRP
mRNA level found in untreated tumours. The most striking
difference was observed in patient 3, who had significantly
reduced (26.6-fold, P=0.014) tumour MRP mRNA levels
following treatment. Results therefore did not suggest any
consistent overall difference between pre- and post-che-
motherapy MRP mRNA levels for either regimen.
Correlations between mRNA levels of the MRP and MDR1
genes in untreated TCC samples
MDRI mRNA levels were also determined in each of the
untreated TCC samples analysed (n=24), and were found to
vary over a 32-fold range (low, 3 x 10-7; high, 9.52 x 10-6).
No significant correlations were observed between MRP and
MDR] mRNA levels in intreated TCC (Figure 5; linear
regression analysis, r2=0.002; log regression analysis,
r=0.162). These results provide no evidence to suggest co-
expression or common regulation of the MDRJ and MRP
genes in TCC of the bladder.
Discussion
We have demonstrated that MRP mRNA is widely expressed
in both transitional cell carcinoma and normal bladder tissue,
with quantifiable gene transcripts detectable in all samples
analysed, and a considerable level of variation (190-fold)
observed between individual untreated bladder tumours. No
other studies could be found that have investigated variations
in MRP mRNA levels within a given solid tumour type,
although recent studies in acute myeloid leukaemia, acute
lymphocytic leukaemia (Schneider et al., 1995) and chronic
lymphocytic leukaemia (Burger et al., 1994) have reported
variation ofMRP mRNA levels between individual untreated
patients (53% (n=29), 128% (n=15) and 63% (n=17)
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coefficients of variance respectively) similar to those presently
reported in untreated bladder tumours [111% (n=24)
coefficient of variance].
By Northern blot analysis, Cole et al. (1992) found that
MRP mRNA was detectable in lung, testis and peripheral
blood mononucleocytes, but was not detectable in placenta,
brain, kidney, salivary gland, uterus, liver and spleen.
Similarly, using an RNAase protection assay, Zaman et al.
(1993) reported MRP mRNA to be readily detectable in a
wide range of normal tissues, with highest levels detected in
lung, spleen, thyroid, testis, bladder, adrenal gland and gall
bladder, and lowest levels detected in kidney, colon, nerve,
ovary, duodenum, placenta, liver and brain. Our results
confirm that MRP gene transcripts are readily detectable in
the normal bladder, and indicate that the pooled mean MRP
mRNA level detected in TCC samples is respectively 2.3- and
4.1-fold lower than those detected in normal peripheral
mononucleocyte and testis samples. In the small number of
normal bladder samples analysed (n= 5), MRP gene
transcript levels varied over a comparable range and level
to those observed in bladder tumours (70% coefficient of
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Figure 4 (a) The relationship between pretreatment MRP
mRNA levels and the response to chemotherapy. Tumour MRP
mRNA levels (mean MRP/18S ratio + s.e.) are shown grouped
according to regimen received and response to chemotherapy
(CR, complete response, W; PR, partial response, M; NR, no
response (no change or progressive disease), _). (b) MRP
mRNA levels (mean MRP/18S ratio + s.e.) in paired samples
taken before (I ) and following ( ) chemotherapy from four
individual patients, shown grouped according to chemotherapy
regimen received. Biopsies were taken from patient 4 at 3 and 6
weeks following the end of treatment. Probability values (by t-test
or Welch's t-test for unequal variances*) for increases/decreases in
expression observed following treatment are shown.
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Figure 3 (a) Mean MRP mRNA levels for each TCC and
normal bladder sample analysed, with each sample represented by
a single point. Tumour samples are shown grouped according to
stage (A) and grade (A), and normal bladder samples are shown
as stripped urothelium (0) or whole bladder wall (*). (b)
Histograms showing the distribution of individual tumour MRP
mRNA levels in groups of high-(G3) and low-(Gl/2) grade
bladder tumours. Tumours are shown grouped according to their
level of MRP mRNA expression. Population mean and median
MRP mRNA levels are shown for each group of tumours.
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variation). Given the similarity between the range and level of
MRP mRNA expression in normal bladder and TCC
samples, it would be of future interest to determine whether
MRP mRNA levels found in individual tumours are indeed
reflective of those found in the surrounding normal tissue by
investigating multiple biopsies from the bladders ofindividual
patients that are commonly taken for prognostic purposes.
Little is currently known regarding the mechanisms of
MRP gene regulation that underlie the variations in MRP
mRNA levels observed between individual tumours. For in
vitro selected MDR cell lines, gene amplification has been
demonstrated to account at least partially for increased MRP
gene expression in the majority of cell lines previously
reported, however, in the absence of any chemotherapeutic
selection pressure, this seems unlikely in untreated tumours.
Zhu and Center (1994) recently cloned the MRP promoter
region from HL60/ADR cells, revealing the presence of
consensus domains for a number of regulatory elements,
including a consensus binding sequence for the c-fos/c-
jun(AP1) transcription factor complex. This suggests that
growth signal transduction pathways and their deregulation
during oncogenic transformation and tumour progression
may play an important role in the transcriptional regulation
of the MRP gene. Indeed, Bordow et al. (1994) recently
reported that MRP mRNA levels were highly correlated
(P=0.0009, n =25) with mRNA levels of the N-myc
oncogene in childhood neuroblastoma. Thus, while studies
have yet to demonstrate a causal link, observations do
suggest that oncogenes and growth factors are likely to
influence MRP gene expression.
The association observed between MRP mRNA expres-
sion and tumour grade may shed some light on the
mechanism of MRP gene regulation in tumours. Our results
show that the proportion of tumours with low MRP mRNA
levels (MRP/18S ratio <1 x 10-5) iS significantly greater in
the high-grade compared with the low- and moderate-grade
group (55% vs 8%). However, it was notable that the
presence of a single high MRP-expressing tumour in the high-
grade group (see Figure 3a) may mask a more pronounced
difference. Because of its markedly high MRP mRNA level,
the histology of this sample was reassessed. This revealed the
tumour to be of mixed nature, with sufficient multiple
squamous cell carcinoma (SCC) elements present among
TCC regions to suggest its reclassification as borderline SCC.
SCC represent <10% of all bladder tumours, and has a
worse prognosis than TCC (<30% 5 year survival;
Raghavan, 1988). Its SCC nature may potentially explain
its atypical MRP mRNA level. More interestingly, this
sample suggests that MRP mRNA levels may be higher in
SCC than TCC of the bladder, and may be worthy of further
investigation, especially given the worse prognosis of SCC
tumours. However, even with the inclusion of this sample,
our results demonstrate a trend towards down-regulation of
MRP mRNA expression in high-grade TCC tumours, and
suggest that this may be a general consequence of the loss of
tumour differentiation and late-stage progression events
associated with high-grade disease.
Varying degrees of lymphocytic infiltration are found in
bladder tumours which, given their relatively high MRP
expression levels, should be considered for their influence on
the tumour measurements. The most extensive data on
lymphocytic infiltration of bladder tumours has been
published by Lipponen et al. (1993) based on 514 patients.
Interestingly, this study reports increased lymphocytic
infiltration in late-stage high-grade tumours, with 26% of
G1/G2 tumours showing moderate or dense infiltration
compared with 68% of G3 tumours. This would tend to
pull the mean tumour MRP levels up in high-grade tumours,
whereas we see a trend down. This in turn would suggest that
the reduction in tumour cell MRP levels we have observed
may be more marked than apparent from the bulk tumour
sample measurements.
The clinicopathological relevance of the reduced MRP
mRNA levels observed in high-grade tumours is uncertain.
Reduced MRP mRNA levels may represent a marker of
advanced disease in TCC of the bladder, and raises questions
about their prognostic significance. The preliminary survival
data accumulated to date (28.1 month mean follow-up in
surviving patients) suggest that low MRP mRNA levels do
not identify a subgroup of high-grade tumours with worse
prognosis, with equivalent mortality rates observed in
subgroups of high-grade tumours with high (MRP/18S
>1x10-5, n=6) and low (MRP/18S <l X -, n=6)
MRP mRNA levels (four out of six patients dead from
their disease in each case). MRP mRNA expression did not
predict tumour recurrence and progression within the group
of superficial bladder tumours studied, however the numbers
involved to date (n = 13) are small, and only two tumours in
this group had low MRP/18S ratios (<1 x 10-5). Further
clinical studies are therefore required to assess whether low
MRP mRNA levels predict an adverse prognosis in super-
ficial disease, as well as data on longer term survival follow-
up in high-grade tumours.
The pattern of MRP mRNA expression observed with
respect to tumour grade is markedly different from that
which we have previously reported for the MDR] gene in
untreated bladder tumours, where pooled mean MDR]
mRNA levels were significantly higher in high-grade than
low-grade tumours, and were associated with a poorer patient
prognosis (Clifford et al., 1994). Thus, despite an apparent
structural and functional similarity, the expression patterns of
the MDRI and MRP genes appear to be markedly different
in bladder cancer, and reflect the differences in their pattern
of expression observed between different tissues (Cole et al.,
1992). The present study demonstrates no correlation
between the mRNA levels of the MDRJ and MRP genes
and thus provides no evidence to suggest co-regulation or
expression of the two genes.
No evidence was found to support a role for high
pretreatment MRP mRNA levels as a negative determinant
of the response of untreated bladder tumours to the CMV or
EPICM regimens, based on the limited number of samples
investigated. Similarly, no consistent evidence was found to
suggest that MRP-mediated drug resistance is selected for
during treatment with either the EPICM or CMV regimens.
Several reasons may potentially explain the lack of
associations observed between MRP mRNA levels and
response. Firstly, that MRP-mediated drug resistance is not
functional at the MRP mRNA levels reported and is
therefore not relevant to bladder cancer, with other
mechanisms of resistance involved in the determination of
response. This question could be further and specifically
tested in vitro using MRP gene down-regulation strategies in
unselected bladder tumour cell lines. Secondly, that with the
regimens used, the MRP-substrate drugs (epirubicin and
vinblastine) are not being administered at sufficiently
efficacious concentrations, and other drugs contained in the
regimen (cisplatin and methotrexate) are responsible for any
tumour responses observed. A critical examination of this
question would require extension of these studies to a larger
population of patients, with chemotherapy regimens invol-
ving therapeutic dose monitoring to achieve controlled
significant doses of those agents to which MRP can confer
resistance. Finally, the timing of post chemotherapy tumour
sampling (at 2-3 weeks following therapy) may not have
allowed sufficient time for tumour repopulation by any
chemotherapy-selected resistant cell subpopulations.
The wide variation in MRP mRNA levels (190-fold)
observed in the high-grade, invasive group of bladder
tumours that are routinely treated by chemotherapy remains
potentially very important in terms of their differential
chemosensitivity. Studies with MRP transfectants and in
vitro selected cell lines (e.g. Grant et al., 1994; Cole et al.,
1992; Zaman et al., 1993; Slovak et al., 1993) have shown
that far smaller increases (approximately 10- to 100-fold) in
MRP mRNA levels are associated with or confer marked
increases in resistance in MDR cells. However, the ranges
over which these variations occur may be different to those
observed in bladder tumours. Some useful initial evidence in
this regard comes from a recent study by Hasegawa et al.MRP gone expression in human bladder cancer
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(1995), who reported the presence of detectable levels of the
MRP protein (by Western blot) in the unselected TCC cell
line, KK47. Using our PCR-based gene transcript assay, we
have independently (Clifford, 1994) demonstrated this cell
line to have an MRP/18S ratio of 8.2 (± 2.7) x 10-5 (mean
+ s.e.), which lies within the range of MRP mRNA levels
presently reported in untreated bladder tumours, thus
suggesting that the MRP mRNA levels observed in bladder
tumours may indeed encode significant levels of the MRP
protein. Further studies are required to determine whether
the variations in MRP mRNA and protein levels observed in
bladder tumours occur over a functionally significant range.
In summary, this study reports a pilot investigation
demonstrating extensive variation in the levels of MRP
mRNA expression in TCC of the bladder, with a trend
towards low levels to be found more frequently in high-grade
invasive TCC of the urinary bladder. However, despite
encouraging in vitro and initial clinical findings, both the
role of the MRP gene in clinical drug resistance and its role
in the normal, non-neoplastic urothelium (and the conse-
quence of variations in expression) still remain to be defined.
The recent development of discriminatory anti-MRP mono-
clonal antibodies (Flens et al., 1994; Hipfner et al., 1994)
should aid the progress of investigations regarding the
relationship between MRP mRNA, protein levels/localisa-
tion and drug resistance in both tumour and cell line samples,
and help to elucidate their significance in terms of tumour
response to chemotherapy.
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